Update on clinical trials in dry Age-related macular degeneration

Taşkintuna, İbrahim; Elsayed, Maram E. A. Abdalla; Schatz, Patrik

doi:10.4103/0974-9233.173134

Cited by 31 publications

(18 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whereas exudative AMD can be treated with vascular endothelial growth factor antagonists (anti-VEGF), no sufficient treatment has been established for the nonexudative form yet. 115 Nevertheless, light-induced oxidative pathology might be reduced under carotenoid supplementation strengthening the MP, and AMD patients are likely to show reduced progression rates of the disease. [116][117][118] A connection between MP and visual function in AMD has also been described.…”

Section: Age-related Macular Degenerationmentioning

confidence: 99%

“…119 However, various studies have published discordant results, and no uniform recommendation on the supplementation of lutein and zeaxanthin has been made so far. 69,111,115,116,[120][121][122][123][124][125][126][127][128] Both forms of AMD may lead to atrophy of the retina in their end-stages. The late stage of nonexudative AMD is called geographic atrophy (GA), and literature uses the term "macular atrophy" in cases of advanced exudative AMD.…”

Section: Age-related Macular Degenerationmentioning

confidence: 99%

See 1 more Smart Citation

Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy

et al. 2018

View full text Add to dashboard Cite

Autofluorescence-based imaging techniques have become very important in the ophthalmological field. Being noninvasive and very sensitive, they are broadly used in clinical routines. Conventional autofluorescence intensity imaging is largely influenced by the strong fluorescence of lipofuscin, a fluorophore that can be found at the level of the retinal pigment epithelium. However, different endogenous retinal fluorophores can be altered in various diseases. Fluorescence lifetime imaging ophthalmoscopy (FLIO) is an imaging modality to investigate the autofluorescence of the human fundus in vivo. It expands the level of information, as an addition to investigating the fluorescence intensity, and autofluorescence lifetimes are captured. The Heidelberg Engineering Spectralis-based fluorescence lifetime imaging ophthalmoscope is used to investigate a 30-deg retinal field centered at the fovea. It detects FAF decays in short [498 to 560 nm, short spectral channel (SSC) and long (560 to 720 nm, long spectral channel (LSC)] spectral channels, the mean fluorescence lifetimes (τm) are calculated using bi- or triexponential approaches. These are meant to be relatively independent of the fluorophore's intensity; therefore, fluorophores with less intense fluorescence can be detected. As an example, FLIO detects the fluorescence of macular pigment, retinal carotenoids that help protect the human fundus from light damages. Furthermore, FLIO is able to detect changes related to various retinal diseases, such as age-related macular degeneration, albinism, Alzheimer's disease, diabetic retinopathy, macular telangiectasia type 2, retinitis pigmentosa, and Stargardt disease. Some of these changes can already be found in healthy eyes and may indicate a risk to developing such diseases. Other changes in already affected eyes seem to indicate disease progression. This review article focuses on providing detailed information on the clinical findings of FLIO. This technique detects not only structural changes at very early stages but also metabolic and disease-related alterations. Therefore, it is a very promising tool that might soon be used for early diagnostics.

show abstract

Section: Age-related Macular Degenerationmentioning

confidence: 99%

Section: Age-related Macular Degenerationmentioning

confidence: 99%

Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…На сегодняшний день представлены сведения о ещё десятке зарегистрированных незавершённых клинических испытаний по применению клеточных технологий в лечении пациентов с ВМД на разных стадиях. Руководители некоторых из них уже публикуют статьи с промежуточными обнадёживающими положитель ными результатами, подтверждающими безопасность, хорошую переносимость и достоверное улучшение зрительных функций у па циентов [20,40].…”

Section: хирургическое лечение с применением стволовых клетокunclassified

Stem cell-based technologies in treatment of age-related macular degeneration patients: current state of the problem

Gayduk

Юрьевич²,

Churashov

et al. 2020

Ophthalmology Reports

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is the most common disease of the macula the area responsible for central vision. With regard to the pathogenesis of AMD, the main focus of most researchers is on the pathological processes occurring in the retinal pigment epithelium (RPE), which is considered as the main target of the disease. For the treatment of the dry form of the disease, which accounts for about 90% of all AMD cases, up to now no effective treatment methods were elaborated, while in the therapy of the wet form, antiangiogenic therapy, photodynamic therapy, and surgical treatment methods have been used with concrete success. Stem cells, possessing enormous therapeutic potential, are gradually being introduced into medical technologies, including ophthalmology. A number of pre-clinical studies have proven the safety of using cultured cells of the RPE, which gave rise to the beginning of clinical trials of the use of stem cells in the treatment of AMD patients. The review analyzes the data of scientific literature on the current understanding of the pathogenesis of AMD, pathogenetically substantiated therapies, including those using cell-based technologies, prospects and problems of using stem cells in the treatment of AMD patients.

show abstract

“…No data are available for the effectiveness of GSK933776 in cognition and, currently, there are no ongoing phase III trials on AD patients, but this antibody is under investigation for the treatment of dry age-related macular degeneration [42]. This eye condition is characterized by the early presence of drusen deposits in the retina containing lipids and Aβ42 that increase the risk of developing the full disease [43]. GSK933776 and other anti-amyloids (RN6G) seem to reduce ocular Aβ with promising results.…”

Section: Second-generation Aβ42 Antibodies: Minimize Inflammationmentioning

confidence: 99%

Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target

Wang¹,

Yan

Hong³

et al. 2017

Neurodegener Dis

View full text Add to dashboard Cite

Background: Available drugs for the global Alzheimer disease (AD) epidemic only treat the symptoms without modifying disease progression. Accumulating evidence supports amyloid-β42 (Aβ42)as the key triggering agent in AD, making it the ideal target for disease-modifying therapies. Preclinical studies provided extensive support for passive Aβ42 immunotherapy, leading to human clinical trials with different antibodies. Objective: Examine the status of clinical trials for passive immunotherapy against Aβ42. Methods: We performed a thorough literature review of passive Aβ42 immunotherapy. Results: Ten anti-Aβ42 antibodies targeting lineal or conformational epitopes have been tested in clinical trials. Antibody engineering and appropriate dosing have overcome undesired side effects, leading to increased safety profiles. Unfortunately, few trials have shown cognitive protection, leading to legitimate questions about the utility of Aβ42 as an AD target. There is still hope that solanezumab, aducanumab, and other ongoing trials will identify antibodies, patient subpopulations, and administration protocols, with consistent clinical benefits. Conclusions: Despite the overall disappointing results, there is still hope that Aβ immunotherapy in presymptomatic patients will prevent neuronal loss and provide significant clinical benefits that can be applied to larger populations as preventive therapies. Advances with other targets may soon provide additional therapeutic options for AD with increased efficacy.

show abstract

Update on clinical trials in dry Age-related macular degeneration

Cited by 31 publications

References 112 publications

Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy

Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy

Stem cell-based technologies in treatment of age-related macular degeneration patients: current state of the problem

Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target

Contact Info

Product

Resources

About